1. Home
  2. RAND vs BDSX Comparison

RAND vs BDSX Comparison

Compare RAND & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$15.96

Market Cap

41.2M

Sector

Finance

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.95

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
BDSX
Founded
1969
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Precision Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.2M
53.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RAND
BDSX
Price
$15.96
$7.95
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
4.7K
63.1K
Earning Date
11-07-2025
11-03-2025
Dividend Yield
7.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,327,287.00
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.29
52 Week Low
$13.25
$3.44
52 Week High
$31.89
$32.20

Technical Indicators

Market Signals
Indicator
RAND
BDSX
Relative Strength Index (RSI) 72.11 52.12
Support Level $13.95 $7.77
Resistance Level $15.49 $8.38
Average True Range (ATR) 0.49 0.57
MACD 0.23 -0.01
Stochastic Oscillator 98.55 60.38

Price Performance

Historical Comparison
RAND
BDSX

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: